Focused On-demand Library for Mediator of RNA polymerase II transcription subunit 31

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9Y3C7

UPID:

MED31_HUMAN

Alternative names:

Mediator complex subunit 31; Mediator complex subunit SOH1

Alternative UPACC:

Q9Y3C7; B2R4L9

Background:

Mediator of RNA polymerase II transcription subunit 31, also known as Mediator complex subunit 31 and Mediator complex subunit SOH1, plays a pivotal role in the regulated transcription of nearly all RNA polymerase II-dependent genes. It acts as a crucial component of the Mediator complex, facilitating the transfer of information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. This protein is instrumental in recruiting the Mediator to promoters through direct interactions with regulatory proteins, serving as a scaffold for assembling a functional preinitiation complex.

Therapeutic significance:

Understanding the role of Mediator of RNA polymerase II transcription subunit 31 could open doors to potential therapeutic strategies.